Attainment of Recommended Lipid Targets in Patients with Familial Hypercholesterolemia: real-world experience with PCSK9 inhibitors

Conclusion Our results suggest that control of lipid levels in patients with FH has improved and that the achievement of guideline-directed goals has been facilitated by access to PCSK9 inhibitors. These observations provide insight into the real-world effectiveness of PCSK9 inhibitor therapy in patients with FH. Teaser Familial Hypercholesterolemia (FH) is characterized by very high levels of low density lipoprotein cholesterol and increased risk of cardiovascular events. We examined the real-world impact of PCSK9 inhibitors on lipid levels in patients in the British Columbia FH Registry. From 2015 to 2017, lipid levels improved in this cohort, and this improvement was due in large part to those patients in whom a PCSK9 inhibitor was used.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research